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Abstract
Introduction: The immunological and homing properties of mesenchymal stem cells (MSCs) provide a potentially
attractive treatment for arthritis. The objective of this study was to determine effects of genetic disparity on the
immunosuppressive potential of MSCs in vitro and in vivo within collagen induced arthritis (CIA).
Methods: The ability of DBA/1, FVB and BALB/c MSC preparations to impact the cytokine release profile of CD3/
CD28 stimulated DBA/1 T cells was assessed in vitro. The effect of systemically delivered MSCs on the progression
of CIA and cytokine production was assessed in vivo.
Results: All MSC preparations suppressed the release of TNFa and augmented the secretion of IL-4 and IL-10 by
stimulated DBA/1 T-cells. However, assessment of the ratio of IFNg to IL-4 production indicated that the more
genetically distant BALB/c MSCs had significantly less immunosuppressive capacity. Systemic delivery of BALB/c
MSC resulted in an exacerbation of CIA disease score in vivo and a higher erosive disease burden. This was not
seen after treatment with syngeneic or partially mismatched MSCs. An increase in serum levels of IL-1b was
observed up to 20 days post treatment with allogeneic MSCs. An initial elevation of IL-17 in these treatment
groups persisted in those treated with fully mismatched BALB/c MSCs. Over the course of the study, there was a
significant suppression of serum IL-17 levels in groups treated with syngeneic MSCs.
Conclusions: These data demonstrate a significant difference in the immunosuppressive properties of syngeneic
and allogeneic MSCs in vitro and in vivo, which needs to be appreciated when developing MSC based therapies for
inflammatory arthritis.
Introduction
Rheumatoid Arthritis (RA) is characterized by systemic
inflammation and local synovitis with pannus formation.
The inflamed synovium is populated with CD4+ T lym-
phocytes, B cells, macrophages and synovial like fibro-
blasts which elaborate pathophysiologically important
cytokines including TNFa, IL-1, IL-4, IL-10 and IL-17
[1-3]. While numerous cells are involved in disease the
ongoing activation of T cells is central in perpetuating
tissue inflammation and damage through stimulation of
mesenchymal cells, including chondrocytes and fibro-
blasts [2]. Early studies demonstrating the central role of
TNFa have been translated into the development of
blocking drugs which have revolutionized the treatment
of RA [4]. Despite recent advances and wide availability
of anti-TNF agents, a considerable number of patients
remain refractory to treatment [5-7]. Other therapeutic
strategies include B cell depletion, inhibition of T cell
co-stimulation and anti IL-6 receptor antibodies [8,9].
While TNFa produced by macrophages is at the center
of a complex cytokine network in inflammatory arthritis,
it is well established that CD4+ T cells play an important
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role in orchestrating and maintaining this immune
response. The production of Th1 cytokines in animal
models is associated with arthritis induction and inflam-
mation and collagen induced arthritis (CIA) is a Th1 dri-
ven disease, while Th2 cytokines are found during
disease remission [10]. However, the role of IFNg in CIA
is complex with a peak in early disease and evidence of a
disease limiting role in late disease decreasing IL-17 pro-
duction and osteoclast precursors while increasing the
activity of T regulatory cells [11]. IL-17 is produced by a
subset of memory CD4+ T lymphocytes termed Th17
cells and plays a critical role in CIA, having a synergistic
effect with TNFa in promoting poor disease outcome
[12-14]. IL-1b has also been implicated in both RA and
CIA; it is known to have a pro-inflammatory role in CIA
which is independent of IL-17 and inhibition with an IL-
1 receptor antagonist results in amelioration of arthritis
[15,16]. The role of anti-inflammatory cytokines in CIA
is less clear; however, IL-4 can inhibit production of
TNFa and reduce T cell proliferation [2].
There is considerable interest in bone marrow derived
mesenchymal stem cells (MSCs) which have the capacity
to differentiate into cells of the connective tissue com-
partment including bone, cartilage and fat. Both mouse
and human MSCs are known to have immunosuppres-
sive effects on T and B cells in vitro [17-20] and this is
likely to be an important aspect of their mode of action.
MSCs can inhibit proliferation of CD4+ and CD8+ T cells
in a dose-dependent manner independently of major his-
tocompatibility complex (MHC) matching with reduced
expression of activation markers [21,22]. The mechan-
isms underlying this immune suppression are not fully
understood and may be mediated by transforming
growth factor-b, hepatocyte growth factor, IL-10 or pros-
taglandin-E2 produced by the cells [21,23,24]. Addition-
ally, MSC immune regulation may be mediated through
secondary effects on other cells, such as increased TNFa
and IL-10 production by dendritic cells and decreased
IFNg production by Th1 cells [25-27].
In vitro studies suggest that the immunosuppressive
properties of MSCs may be useful for in vivo treatment
of inflammatory arthritis [28]. MSCs from healthy donors
can inhibit type II collagen (CII) stimulated proliferation
of T cells from arthritis patients [29]. In addition, adipose
derived stem cells (ASC) can exert profound suppressive
responses on CII-reactive T cells by suppressing CII-
induced T cell proliferation, inhibiting inflammatory
cytokine production and stimulating production of IL-10
by monocytes and T cells. Co-culture of ASCs with
T cells induced the generation of antigen-specific T regu-
latory cells and ASCs were also shown to inhibit produc-
tion of inflammatory factors by activated synovial cells
involved in the destruction of cartilage and bone [30].
Overall, it is clear that MSCs exert immunosuppressive
effects on several classes of lymphocytes through
mechanisms that may be exploited in a clinical setting.
As MSCs may migrate to sites of injury in vivo it is feasi-
ble to suggest that targeting of the cells to inflamed joints
might have a therapeutic effect on local arthritis through
MSC-mediated immunosuppression [31,32]. An addi-
tional property of MSCs is their status as immune privi-
leged cells with low expression of MHC II [33,34] and an
absence of co-stimulatory molecules [21,35]. This raises
the prospect of allogeneic cell therapy in a variety of dis-
ease models. However, translation of compelling in vitro
data to pre-clinical studies of arthritis has resulted in
conflicting data [30,36-41]. Studies using either single or
multiple injections of MSCs have shown varying degrees
of disease amelioration or exacerbation. MSCs have been
delivered at various time points, including at disease
induction or during established disease, and generally at
doses of 1 × 106 cells, although in some cases up to 5 ×
106 cells. In an effort to shed further light on the disease-
modifying effects of allogeneic MSC transplantation, we
looked at the effects of genetic disparity between systemi-
cally delivered MSCs and the host recipient. We hypothe-
sized that the degree of mismatch between donor and
host may exert a profound effect on their immunosup-
pressive properties. We studied this in vitro by examining
the interactions between MSCs and T cells when the cells
were syngeneic, partially mismatched or fully mis-
matched. We achieved this by examining the effects of
MSCs from DBA/1 mice on T cells from the same strain
(syngeneic), from FVB mice (partially mismatched) and
from BALB/c mice (fully mismatched). For in vivo studies
we considered it important to establish if the genetic
background affected the ability of a single injection of
MSCs at the time of onset of clinical disease to alter dis-
ease progression in CIA.
Materials and methods
Mesenchymal stem cell isolation and characterization
MSCs were isolated from the bone marrow of eight- to
ten-week old BALB/c and FVB mice as described pre-
viously [42]. For DBA/1 mice collagenase digestion of the
marrow was carried out before MSC expansion in com-
plete expansion medium (Iscove’s modified eagle’s med-
ium, 9% horse and 9% fetal bovine serum (FBS), 1%
penicillin and streptomycin (P/S), 1% L-glutamine;
CEM). It has been demonstrated that murine bone mar-
row derived MSCs isolated using collagenase digestion
retain the characteristic properties of MSC [43]. Briefly,
mononuclear cells from two femurs were plated in a
T-175 flask. Sufficient fibroblastic-like cells were
obtained at the end of P1 to replate at 50 cells/cm2 and
4,500 cells/cm2 were plated for subsequent passages with
about a 10-fold increase in cell number by confluency
(seven days). Expression of cell surface antigens was
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quantified using flow cytometry. Briefly, 200,000 cells
were used per antibody staining. After blocking in PBS
with 2% FBS, 1% rat serum for 30 minutes on ice, cells
were centrifuged at 400 g for 5 minutes and resuspended
in 100μl of the appropriate antibody diluted in PBS with
2% FBS. CD73, CD34 and CD31 antibodies were used at
1:200, Sca1, CD105, CD44 and CD29 at 1:400 and CD45
at 1:500. Cells were incubated on ice for 30 minutes in
the dark, washed in PBS with 2% FBS and resuspended in
200μl prior to analysis on the BD FACS Canto flow cyt-
ometer. All antibodies were from eBioscience (Hatfield,
UK) except for anti-CD45 (Becton Dickinson, Franklin
Lakes, NJ, USA). All MSC preparations were stimulated
to undergo adipogenesis, osteogenesis and chondrogen-
esis as described previously using CEM as the basal med-
ium for osteogenesis and adipogenesis [44]. Adipogenesis
was confirmed with Oil Red O staining for lipid vacuoles.
Osteogenesis was assessed using quantitation of calcium
with the Calcium Liquicolour Kit (StanBio, Boerne, TX,
USA) and mineral deposition visualized using alizarin
red. For chondrogenesis cell pellets were digested with
papain and glycosaminoglycan (GAG) was determined
using the dimethylmethylene blue assay. Histological sec-
tions (5 µM) of formalin-fixed pellets were stained for
the presence of GAG using toluidine blue.
Collagen induced arthritis
All animal work was carried out with approval from the
local Institutional Animal Care and Use Committee.
Male mice seven- to nine-weeks old were used for all
arthritis induction as female DBA/1 mice are not suscep-
tible to CIA. Mice were obtained from a commercial sup-
plier and housed in groups of two or three; room
temperature and food, water supply and general health
were assessed daily. There were 12 mice included in each
CII treatment group. CIA was induced in male DBA/1
mice by immunization with 50 µL bovine bovine CII
emulsified in 50 µL complete Freund’s adjuvant followed
by a booster immunization in incomplete adjuvant at
21 days. MSCs from eight- to ten-week old mice at pas-
sage four to six were delivered intravenously on day 21
via the lateral tail vein; 1 × 106 MSCs were suspended in
100 µl of PBS and used within 30 minutes of preparation.
Cell counts using trypan blue exclusion of dead cells con-
firmed >95% cell viability for MSCs harvested and stored
by these methods for all three strains (results not shown).
A control group received PBS. Clinical scores were calcu-
lated based on the paw thickness across the metatarso-
phalangeal joints and dactylitis as follows: paw <2 mm =
0 points, paw 2 to 3 mm = 2 points, paw 3 to 4 mm = 3
points, paw 4 to 5 mm = 4 points, paw 5 to 6 mm = 5
points, swollen wrist or ankle = 3 points, swollen digit =
1 point. The scoring system ensured that disease activity
reflected by dactylitis only was not overlooked and
avoided reliance on measurement in increments <1 mm
and subjective assessment of erythema. The clinical score
was assessed every 24 hours. Blood was collected and
serum cytokine levels assayed using a Bio-Plex 200 cyto-
kine array. Knees were fixed in formalin, processed, par-
affin-embedded, sectioned and stained with a modified
Mallory stain [45].
In vitro T cell stimulation studies
Spleens and submandibular lymph nodes from DBA/1
mice were harvested, placed in ice-cold PBS/10% FBS,
shredded and passed through a 70 µm mesh. A combina-
tion of splenic and nodal cells were harvested to optimize
cell numbers and approximately 20 × 106 cells were iso-
lated per mouse; for each experiment cells from three
DBA/1 mice were mixed. The resulting single cell sus-
pension was centrifuged at 120 g for 10 minutes and
resuspended in lysis buffer (Invitrogen, Dublin, Ireland).
After three minutes incubation at room temperature,
cold PBS/2% FBS was added and the sample centrifuged
for 10 minutes. Cells were washed in PBS/2% FBS and
either resuspended in medium (HG-DMEM, 10% FBS,
2% P/S, 1% HEPES, 12 µM L-glutamine and 1% non
essential amino acids) or used for T cell isolation.
CD4+ T cells were isolated by positive selection using
murine CD4 Dynabeads (Miltenyi Biotech, Bergisch
Gladbach, Germany). Cells were resuspended in MACS
buffer with CD4 microbeads and CD4- cells were sepa-
rated on an octoMACS magnetic separator (Miltenyi Bio-
tech) according to the manufacturer’s instructions. The
CD4+ cells were resuspended in DMEM/10% FBS and
stimulated with anti-CD3/anti-CD28 beads (1:1 ratio)
(Dynabeads mouse T cell expander, Invitrogen) for
24 hours in 96-well tissue culture plates. The activated
T cells were washed and 1 × 105 T cells were replated
with adherent MSCs (passage four to six, six donor
mice), at an MSC:CD4 cell ratio of 1:10 or 1:1, and re-sti-
mulated by the same method. The re-activation of T cells
at the time of addition to MSC cultures was designed to
mimic the in vivo scenario where mice received the boos-
ter immunization which triggers overt inflammation at
the time of MSC delivery. Culture supernatants were col-
lected at 24 hours for determination of cytokine concen-
trations by ELISA (eBioscience Mouse Th1/Th2 and
Mouse TNFa ELISA Sets).
Statistics
Statistical analysis was performed using StatsDirect®
software. In all instances the Shapiro Wilks test was
used to confirm a normal distribution. For direct com-
parisons t-tests or Mann Whitney tests were used where
appropriate for parametric/non-parametric data, respec-
tively. Comparison between groups was carried out
using analysis of variance (ANOVA) with post-hoc
Tukey testing.
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Results
MSC isolation
MSCs were isolated from bone marrow of DBA/1, FVB
and BALB/c mice. DBA/1 and FVB mice carry the MHC
H2q haplotype while BALB/c mice carry the H2d haplo-
type. All three MSC strains had a characteristic fibroblastic
morphology and were differentiated under appropriate
conditions into chondrocytes, adipocytes and osteocytes.
Although adipogenesis and chondrogenesis were similar
between all three strains, FVB cells had the highest osteo-
genic potential. All three MSCs preparations were over
95% positive for CD29 and CD44. Detection of CD105 and
Sca 1 varied between strains as has been shown previously
[42] with approximately 17% of BALB/c MSCs positive for
CD73. All three strains of MSCs were negative for CD45,
CD34 and CD31 (Figure 1, Table 1) [20,35,42,46]. Cells
also lacked expression of MHC II (results not shown).
In vitro cytokine T cell studies
TNFa and IFNg were detected in the supernatant of
CD4+ T cells 24 hours post-stimulation with CD3/CD28
beads. Only trace levels were measured in the superna-
tants from unstimulated T cells with and without MSCs,
and cultures containing only MSCs (results not shown).
The secretion of TNFa by stimulated CD4+ T cells was
significantly suppressed by all MSC preparations at
ratios of 1:10 and 1:1 (Figure 2A). Syngeneic (DBA/1)
and partially mismatched (FVB) MSCs did not signifi-
cantly affect IFNg secretion by DBA/1 CD4+ T cells at
24 hours (Figure 2B). Similarly, fully mismatched BALB/
c MSCs did not alter IFNg levels at a ratio of 1:10; how-
ever, there was a significant increase in IFNg production
by T cells co-cultured with mismatched MSCs at the
higher ratio of 1:1 (Figure 2B).
IL-4 secretion by stimulated CD4+ T cells was
detected at 24 hours. This was significantly increased in
cultures with MSCs from each genetic background at
the 1:1 ratio. With a lower MSC to CD4+ T cell ratio of
1:10 only syngeneic MSCs increased IL-4 secretion; this
was significantly higher than IL-4 detected in cultures
containing either mismatched MSC at this ratio. With
the exception of partially mismatched MSCs at a ratio
of 1:10, all MSCs increased IL-10 production by stimu-
lated T cells after 24 hours (Figure 2D).
The ratio of Th1:Th2 cytokine production was deter-
mined based on IFNg and IL-4 levels. After 24 hours this
Th1:Th2 ratio was reduced in cultures containing syn-
geneic and partially mismatched MSC demonstrating a
shift towards Th2 production compared to controls; this
was significant at the higher cell ratio of 1:1 (Figure 2E).
There was no significant difference between Th1:Th2 ratio
of T cells cultured with fully mismatched (BALB/c) MSCs
compared to controls at either the 1:10 or 1:1 MSC:T cell
ratio. However, there was a significant difference between
the Th1:Th2 cytokine ratio of T cells co-cultured with
BALB/c MSCs compared to that of either the syngeneic or
partially mismatched cultures (Figure 2E).
In all groups, controls of un-stimulated CD4+ T cells
with and without MSCs were included; no production
of pro or anti-inflammatory cytokines was seen in these
groups (results not shown).
MHC mismatch influences the effect of murine MSCs on
disease progression in CIA
CIA was induced in male DBA/1 mice by immunization
with bovine IIC. Twenty-one days later a booster immu-
nization was given along with an intravenous dose of
MSCs, either syngeneic, partially matched or mis-
matched. Clinical scores were calculated based on the
paw thickness across the metatarsophalangeal joints
(Figure 3D) and dactylitis (Figure 3E); all mice devel-
oped obvious signs of arthritis. The systemic delivery of
syngeneic MSCs had no effect on disease progression in
CIA when compared to mice receiving vehicle control
alone (Figure 3A). The delivery of H-2 matched allo-
geneic FVB MSCs appeared to worsen disease progres-
sion but this was not statistically significant (Figure 3B).
However, infusion of allogeneic H-2 mismatched BALB/
c MSCs resulted in significantly higher disease scores
when compared to vehicle controls from day nine post-
booster to the end of the experiment (Figure 3C). Histo-
logical evidence of erosive disease in the paw, ankle and
knee joints of mice with CIA has been demonstrated
previously [38,47]. In the present study knee joints were
examined histologically to assess for inflammatory dis-
ease not evident on clinical examination and 95% of all
knees analyzed had evidence of histological synovitis.
Furthermore, erosive disease was demonstrated in 50%
of mice receiving vehicle control, syngeneic or partially
mismatched MSCs compared to 70% of mice receiving
fully mismatched BALB/c MSCs (Figure 4B and 4D).
This difference did not reach statistical significance and
the mean clinical scores between erosive and non-ero-
sive groups were similar (results not shown). Evidence
of erosive disease was also found following histological
examination of the interphalangeal joint of the paw
(Figure 4F and 4G).
Serum was collected 7 and 20 days after booster immu-
nization and cytokine levels were analyzed. Serum TNFa
levels were elevated in CIA mice treated with vehicle only
compared to non-arthritis controls. There was no signifi-
cant difference in TNFa levels between treatment groups
or compared to vehicle controls (Figure 5A). At day seven
levels of IFNg were increased in mice receiving MSCs
from all genetic backgrounds. This effect was transient
and there was no significant difference between groups at
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Figure 1 Mouse MSC characteristics. Representative images of BALB/c MSCs showing A, fibroblastic morphology of MSCs, B, adipogenesis
with fat vacuoles stained with Oil Red O and C, osteogenesis with Alizarin Red staining (scale 500 μm). D, proteoglycan (GAG) per 105 cell pellet
demonstrating chondrogenic potential in the presence of TGFb3 and BMP2. Analysis was performed in triplicate pellets; * P <0.05 (Mann
Whitney U testing). E, histological confirmation of chondrogenesis by BALB/c MSC using toluidine blue staining (scale 200μm). F, flow cytometric
analysis of BALB/c, FVB and DBA/1 MSCs showing them to be positive for CD73 and CD105, and negative for CD45. G, H, I, calcium deposition
demonstrating osteogenesis; *P <0.05, **P <0.001 (unpaired T test). Data represents mean ± standard deviation of triplicate cultures. BMP, bone
morphogenetic protein; GAG, glycosaminoglycan; MSC, mesenchymal stem cells; TGFb, transforming growth factor beta.
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20 days (Figure 5B). At seven days IL-1b was elevated in
all treatment groups compared to controls. This persisted
in the serum of mice treated with either FVB or BALB/c
MSCs. However, serum levels in mice treated with either
PBS or syngeneic MSCs were lower than those treated
with allogeneic MSCs (Figure 5C). IL-17 levels were ele-
vated in all mice at seven days compared to non-arthritis
controls and remained persistently elevated in mice trea-
ted with BALB/c MSCs. There was a highly significant
suppression of IL-17 levels in the serum levels of mice
treated with syngeneic MSCs over the course of the study
(Figure 5D). Serum IL-10 levels were elevated only at the
seven day time point in MSC treated mice compared to
non-arthritic controls (Figure 5E). Serum IL-4 was not
detectable at either 7 or 20 days (results not shown).
Discussion
The ability of MSCs to suppress T cell proliferation and
activation in vitro and their ability to promote repair sug-
gest that they may be beneficial in treating inflammatory
arthritis. However, studies using the CIA mouse model
have been inconclusive with results varying from no ben-
efit to exacerbation of disease [23,29-32]. Studies have
used either MSC delivery at a single time point or multi-
ple injections. We opted to use a single injection to
directly compare the effect of single MSC strains and
avoid confounding factors such as the development of an
immune response to the MSC. Variations in the method
of CIA induction, mouse strains used for MSC prepara-
tion, scoring systems, timing, cell number, and delivery
makes it difficult to compare these published studies
(Table 2) [48]. However, data suggest that any beneficial
effect of MSCs may be mediated through the suppression
of the Th1 and Th17 driven responses along with an
increased antigen specific T regulatory cell response
[40,48,49]. This study represents the first direct compari-
son of the effect of different murine MSC strains on the
progression of CIA and does not demonstrate any pro-
tective effect of MSCs. Indeed, BALB/c MSCs clearly exa-
cerbated disease both biochemically and clinically while
FVB MSCs showed a trend towards increased disease
severity with associated increases in host IL-1b produc-
tion. Additionally, the disease scores seen in BALB/c
treated mice were significantly higher than controls but
did not reach statistical significance when compared to
other MSC treated groups; this reinforces the lack of any
amelioration of disease with MSCs and perhaps suggests
a subtle subclinical negative impact on arthritis even in
syngeneic MSC treated mice.
Several studies have demonstrated the immune privi-
leged status of MSCs [24,33]. However, others have sug-
gested that allogeneic MSCs can elicit a host immune
response [50,51] and genetic disparity reduced the thera-
peutic benefit of MSCs in rat models of ischemic heart
disease [52]. In particular, recent data in rat heart allo-
graft studies demonstrated the presence of activated
T cells in secondary lymphatic organs following the
administration of MHC mismatched MSCs suggesting
that allogeneic MSCs may elicit an immune response
[53]. The ability of MSCs to suppress T cell proliferation
has previously been demonstrated with Carboxyfluores-
cein succinimidyl ester (CFSE) staining [54]. Here, we
focused on the effect of MSCs on cytokine production
and have demonstrated a superior ability of syngeneic
MSCs to suppress T cell responses in vitro with a
decrease in pro-inflammatory cytokine production and
Table 1 Bone marrow stromal cells from all three mouse strains had characteristics of mesenchymal stem cells in
terms of morphology, differentiation capacity and cell surface markers.
Mouse Strain DBA/1 FVB BALB/c
MHC H2 Haplotype H2q H2q H2d
Morphology Fibroblastic Fibroblastic Fibroblastic
Adipogenesis Positive Positive Positive
Osteogenesisa
(μg Ca/well)
6.9 ± 1.6 48.0 ± 0.9 11.9 ± 0.2
Chondrogenesisa
(μg GAG/pellet)
5.6 ± 0.3 5.6 ± 0.5 5.6 ± 0.3
CD73b 64.8 97 17.2
CD105b 82 49.5 97.9
Sca 1b 89.9 67.5 53
CD29 99.2 99.4 96.2
CD44 95.1 98.7 99.7
CD45b 0.6 4 0.6
CD34b 0.4 0.4 0.8
CD31b 0.4 0.5 1.3
aData represents mean ± standard deviation of triplicate assays; b % positive cells; GAG, glycosaminoglycan; MHC, major histocompatibility complex.
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an alteration of the Th1:Th2 ratio. MHC mismatched
allogeneic MSCs not only had less immunosuppressive
effects in vitro compared to MHC matched cells but had
a deleterious effect on disease progression in vivo. Fully
mismatched BALB/c MSCs were the only cells which
resulted in increased serum TNFa levels at day seven
while all three stains of MSCs resulted in elevated serum
IFNg. By day 20 the effects on IFNg production were lost
while only syngeneic DBA/1 cells resulted in a significant
suppression of TNFa production compared to mice
treated with vehicle alone. It was also demonstrated that
all three strains of MSCs augmented the production of
both IL-1b and IL-17. This effect was sustained in mice
treated with either allogeneic cell with respect to IL-1b
while only fully mismatched BALB/c MSCs had the effect
of persistently elevating IL-17 levels by day 20. Interest-
ingly, this elevation in pro-inflammatory cytokines was
significantly suppressed in mice treated with DBA/1 cells
by day 20 after disease induction. Taken together these
data demonstrate an early increase in systemic
Figure 2 The effect of MSCs on cytokine production by CD4+ T cells. Control groups were CD4+ DBA/1 T cells stimulated with CD3/CD28
beads. DBA/1 (syngeneic), FVB (partially mismatched) or BALB/c (fully mismatched) MSCs were co-cultured with DBA/1 CD4+ T cells at a ratio of
either 1:10 or 1:1. A, Co-culture with MSCs decreased TNFa secretion compared to controls independently of the genetic background of the
MSC, *P <0.05 (2-way ANOVA). B, BALB/c MSCs increased IFNg production compared to controls at the ratio of 1:1, *P <0.05 (2-way ANOVA).
C, DBA/1 MSCs augmented IL-4 production by CD4+ T cells at both ratios. This was also seen with FVB and BALB/c MSCs at the ratio of 1:1,
**P <0.01 (2-way ANOVA). D, With the exception of FVB MSCs at a ratio of 1:10, the addition of MSCs resulted in an increase in IL-10 production,
*P <0.05 (2-way ANOVA). E, IFNg:IL-4 was taken to represent Th1:Th2 cytokine production by stimulated T cells. Co-culture with DBA/1 or FVB
MSCs (1:1) significantly suppressed this ratio compared to controls, **P <0.01 (2-way ANOVA). This was not seen when T cells were co-cultured
with BALB/c MSCs. The Th1:Th2 ratio of T cells co-cultured with BALB/c MSCs was significantly higher than either the syngeneic or partially
mismatched MSC groups, *P <0.05 (2-way ANOVA). Throughout n = 3, data represents mean ± standard deviation. ANOVA, analysis of variance;
IFNg, interferon gamma; IL-10, interleukin 10; IL-4, interleukin 4; MSC, mesenchymal stem cells; n, number; Th, T helper cell; TNFa, tumor necrosis
factor alpha.
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inflammation in mice with arthritis treated with MSCs
which is mediated predominantly through IFNg, IL-1b
and IL-17. While treatment with syngeneic MSCs is
insufficient to suppress pro-inflammatory cytokine pro-
duction at seven days, with time they have the effect of
suppressing both IL-17 and IL-1b secretion. This may
relate to increased survival of the cells in vivo or, given
the clinical worsening of disease, a true deleterious effect
of allogeneic MSCs on arthritis progression in an inflam-
matory environment. It has been reported that pre-sti-
mulation of MSCs with IFNg may have the desirable
effect of augmenting MSC immunosuppression in vitro
[53]; however, it is clear that the inflammatory milieu of
CIA does not facilitate this phenomenon. In vivo IL-4
levels were below detectable limits but a significant
increase in IL-10 was demonstrated at day seven in all
three treatment groups. While it has previously been
shown that MSCs transduced to express IL-10 can ame-
liorate disease and the suppression of arthritis by adi-
pose-derived MSCs was associated with increased
synovial IL-10 levels [30,38], only a transient increase in
this cytokine was demonstrated here. This was not sus-
tained to 20 days and the impact of the expected MSC
effect of increased IL-10 production was not sufficient to
impact arthritis progression.
The conflicting results regarding the potential role of
MSCs in arthritis have recently been highlighted [48]. By
comparing MSCs from different murine strains in CIA
under identical experimental conditions, these data go
some way to addressing the conflicting results in previous
studies. It has been demonstrated that, despite their low
immunogenicity, the genetic mismatch between the MSC
and host has a significant impact on the ability of MSCs to
alter disease progression. Furthermore, the effect of MSCs
on disease progression appears to be mediated predomi-
nantly by alterations in host IL-17 and IL-1b production.
Conclusions
The potential of MSCs to treat conditions such as
arthritis may help us to meet the challenge of inducing
remission and joint regeneration in patients with disease
refractory to conventional treatment options. However,
before translation to the bedside it is of fundamental
importance that we fully understand pre-clinical data.
While CIA is a reliable model of RA which continues to
be used successfully in the development of therapeutics,
Figure 3 The effect of systemically infused MSCs on the progression of CIA in DBA/1 mice. A, Intravenous (iv) infusion of syngeneic DBA/
1 MSCs at the time of booster immunization had no effect on disease progression. B, While there appeared to be some worsening of disease
progression after iv delivery of partially mismatched FVB MSCs, this did not reach statistical significance. C, Systemic delivery of fully mismatched
BALB/c MSCs resulted in a significant exacerbation of disease progression compared to control groups which received vehicle alone. D,
Representative images of swollen hind paws ranging from normal (top image) to grossly swollen (bottom image). E, Representative image of
dactylitis in a single digit. All experiments were performed with n = 12 and results are represented as mean ± standard deviation. *P <0.05,
Shapiro Wilks testing for normal distribution followed by unpaired T and Mann Whitney U tests. CIA, collagen induced arthritis; MSC,
mesenchymal stem cells; n, number.
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Figure 4 Histological analyses of knee joints. Fifty percent of the mice treated with vehicle control, syngeneic or partially mismatched MSCs
had erosive disease compared to 70% of those treated with fully mismatched MSCs. A, B, A normal knee joint is illustrated (scale bar 500 μm
and 125 μm, respectively). C, D, Synovial hypertrophy with erosive disease in the knee joint (black arrow) (scale bar 500 μm and 125 μm,
respectively). E, A control interphalangeal joint (IPJ) of the paw (500 μm), F, IPJ with synovial hypertrophy and early erosive disease (black arrow)
(500 μm) and G, a severely diseased IPJ with synovial hypertrophy and extensive erosive disease (black arrows); scale bars, 500 μm. MSC,
mesenchymal stem cells.
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our data clearly demonstrate that a single injection of
MSCs from different genetic backgrounds has disparate
effects on disease progression as demonstrated in clini-
cal scores and serum cytokine levels. This suggests that
further studies looking at the effect of varying cell
numbers and repeated delivery of MSCs are warranted
in the future. These data need to be strongly considered
when both analyzing and developing pre-clinical studies
of inflammatory conditions if the transition of MSCs


































































































































































































































Figure 5 Serum levels of pro-inflammatory cytokines. A, At both 7 and 20 days after booster, and onset of CIA, TNFa levels were raised
significantly in mice receiving vehicle alone (PBS) compared to pre-CIA control levels. TNFa levels were also elevated in mice treated with BALB/
c MSCs at seven days. At day 20 TNFa levels were significantly suppressed only in DBA/1 treated mice compared to the PBS group. B, IFNg
levels were elevated in mice treated with any strain of MSC at seven days compared to pre-CIA controls. At 20 days there was a trend towards
elevated IFNg levels in all groups but this did not reach statistical significance. C, At seven days IL-1b was elevated in all groups, P <0.05 (2-way
ANOVA). At 20 days elevated levels persisted in mice treated with allogeneic MSCs; this was significant compared to groups treated with either
PBS vehicle or syngeneic MSCs, P <0.05 (2-way ANOVA). D, IL-17 levels were significantly elevated on day seven in all treatment groups. By day
20, IL-17 levels were significantly raised only in vehicle treated mice and those treated with fully MHC mismatched allogeneic MSCs (BALB/c).
The level of IL-17 in mice treated with syngeneic MSCs was significantly lower at day 20 than all other treatment groups at this timepoint and
also when compared to DBA/1 treated mice at day seven, P <0.05 (2-way ANOVA). E, At day seven there was an increase in IL-10 levels in all
groups treated with MSCs compared to untreated controls. This effect was not seen at day 20. There were 12 mice per treatment group and all
measurements were assayed in triplicate, * P <0.05 (2-way ANOVA). Data represents mean ± standard deviation. ANOVA, analysis of variance; CIA,
collagen induced arthritis; IFNg, interferon gamma; IL-1b, interleukin 1 beta; IL-10, interleukin10; IL-17, interleukin 17; MHC, major
histocompatibility complex; MSC, mesenchymal stem cells; PBS, phosphate-buffered saline; TNFa, tumor necrosis factor alpha.
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